DGAP-Adhoc: STADA Arzneimittel AG: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA"s shareholders from 75 percent to 67,5 percent - acceptance period extended until June 22, 2017

2017. június 07., szerda, 18:09





DGAP-Ad-hoc: STADA Arzneimittel AG / Key word(s): Miscellaneous


STADA Arzneimittel AG: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA"s shareholders from 75 percent to 67,5 percent - acceptance period extended until June 22, 2017


07-Jun-2017 / 18:09 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.



Bad Vilbel, June 7, 2017 - Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, reduced the minimum acceptance threshold for its voluntary public takeover offer for all outstanding shares of STADA Arzneimittel AG from 75 percent to 67,5 percent today. As a result of the lowering of the minimum acceptance threshold, the acceptance period originally expiring on June 8, 2017 will be extended by two weeks and will now end on June 22, 2017.

The Executive Board and Supervisory Board will continue to recommend to the shareholders of STADA Arzneimittel AG to accept the offer as it is in the best interest of the company and its stakeholders. The Executive Board and Supervisory Board also think that the total compensation of Euro 66.00 per STADA share continues to adequately reflect the enterprise value and represents the financially most attractive offer. All other offer conditions remain unchanged. The Executive Board and Supervisory Board will publish an additional statement on the modified offer in a timely manner pursuant to the provisions of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz).



 



Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel - Germany /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de



Or visit us in the Internet at www.stada.com.










07-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de




























Language: English
Company: STADA Arzneimittel AG

Stadastraße 2-18

61118 Bad Vilbel

Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange





 
End of Announcement DGAP News Service




581367  07-Jun-2017 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=581367&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.